Medline reports robust revenue growth in Q1 2026 but flags higher tariff costs squeezing profitability.
Medline posted strong sales growth in Q1 2026, driven by increased demand across key product lines. The company highlighted that revenue expansion was partially offset by rising tariff-related expenses, which weighed on margins.
Analysts had anticipated a modest improvement in profitability, but tariff costs exceeded expectations. Comparable quarterly results from prior years showed stable margins, underscoring the impact of recent trade policy shifts.
Shares showed muted movement in pre-market trading as investors assessed the mixed performance metrics.